Year |
Citation |
Score |
2005 |
Jia RR, Gou YL, Ho LS, Ng CP, Tan NH, Chan HC. Anti-apoptotic activity of Bak Foong Pills and its ingredients on 6-hydroxydopamine-induced neurotoxicity in PC12 cells. Cell Biology International. 29: 835-42. PMID 16154779 DOI: 10.1016/j.cellbi.2005.03.025 |
0.396 |
|
2002 |
Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Molecular Cancer Therapeutics. 1: 1051-8. PMID 12481428 |
0.718 |
|
2002 |
Ng CP, Zisman A, Bonavida B. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. The Prostate. 53: 286-99. PMID 12430140 DOI: 10.1002/Pros.10155 |
0.735 |
|
2002 |
Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Advances in Cancer Research. 85: 145-74. PMID 12374285 DOI: 10.1016/S0065-230X(02)85005-9 |
0.713 |
|
2002 |
Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 836-45. PMID 11895917 |
0.497 |
|
2001 |
Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 459-71. PMID 11759069 DOI: 10.1097/00002371-200111000-00003 |
0.701 |
|
2001 |
Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3874-83. PMID 11751478 |
0.761 |
|
1999 |
Van Ophoven A, Ng CP, Patel B, Bonavida B, Belldegrun A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature. Prostate Cancer and Prostatic Diseases. 2: 227-233. PMID 12497168 DOI: 10.1038/Sj.Pcan.4500373 |
0.657 |
|
1999 |
Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). International Journal of Oncology. 15: 793-802. PMID 10493964 DOI: 10.3892/Ijo.15.4.793 |
0.71 |
|
1997 |
Uslu R, Borsellino N, Frost P, Gárban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 3: 963-72. PMID 9815772 |
0.663 |
|
1997 |
Frost P, Ng CP, Belldegrun A, Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cellular Immunology. 180: 70-83. PMID 9316641 DOI: 10.1006/Cimm.1997.1169 |
0.645 |
|
Show low-probability matches. |